-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Facing clinical needs and focusing on the international frontier, Li Zhanguo's team from Peking University People's Hospital has published 6 papers
on the mechanism and treatment of rheumatoid arthritis and Sjogren's syndrome in first-class journals such as Lancet RH, JAMA Network Open, and Science Advances.
(1) The Lancet Regional Health is a study led by Peking University People's Hospital and participated by 17 centers of the Rheumatoid Arthritis Professional Group (RA-SIG) of the Asia-Pacific Rheumatology Alliance (APLAR), which conducted a real-world cross-sectional study of RA remission rate in APLAR countries and regions, and explored the relevant factors of drug treatment and clinical remission of this disease
。 The results were presented in The Lancet Regional Health (WP) under the title "Clinical remission of rheumatoid arthritis in a multicenter real-world study in Asia-Pacific region.
" ）” 2021,12; 15:100240 (click to read).
Sun Xing, Li Ru, and Cai Yueming are the joint works of this article, and Li Zhanguo and Li Ru are the joint correspondence
.
This research was supported
by the Macao Science and Technology Development Fund, Beijing Key Laboratory of Rheumatology, Beijing Rheumatoid Arthritis Key Special Fund of Beijing Municipal Science and Technology Commission, and Peking University Tsinghua Joint Center for Life Sciences (CLS).
Science Advances The rheumatology and immunology team of Peking University People's Hospital collaborated with the Beijing Genomics Institute to publish a research paper on the regulation of rheumatoid arthritis by intestinal flora in Science Advances Intestinal butyrate-metabolizing species contribute to autoantibody production and bone erosion in rheumatoid arthritis, and found an imbalance between butyric acid producing bacteria and butyric acid bacteria in RA patients through metagenomic and metabolomic analysis.
Associated with
the production of anti-CCP antibodies and joint deformities in patients.
This article covers basic, clinical and translational research
on rheumatoid arthritis.
Professor He Jing, postdoctoral fellow Li Jing, Department of Rheumatology and Immunology, Peking University People's Hospital, Yanan Chu from Beijing Genomics Research Institute, and Meng Qingren from Southern University of Science and Technology are co-first authors
of the paper.
Professor Li Zhanguo of Peking University People's Hospital and Peking University-Tsinghua Joint Center for Life Sciences, and Associate Researcher Kang Yu and Professor Yu Jun of Beijing Genomics Research Institute are co-corresponding authors
.
The clinical and scientific research team of the Department of Rheumatology and Immunology participated in the project and jointly completed the project
.
(3) Signal Transduction and Targeted Therapy In March 2022, Zhang Xiaoying et al.
published a research result of immunotherapy for rheumatoid arthritis in the journal Signal Transduction and Targeted Therapy Efficacy and safety of Ld-IL2 in combination with MTX in patients with active RA: a randomized trial
。 Demonstrated the effectiveness and safety
of low-dose IL-2 in the treatment of rheumatoid arthritis.
The authors also analyzed the predictors of efficacy in low-dose IL-2 therapy, the mechanism of methotrexate resistance, and the possible reversal of Lowdose IL2, providing a clinical and experimental basis
for this novel immunotherapy for rheumatoid arthritis.
Dr.
Zhang Xiaoying is the first author of this paper, and Professor Li Zhanguo and Professor He Jing are the corresponding authors
.
(4) Advanced Science In August 2022, Professor Li Zhanguo's research group and Professor Wang Jun's research group of the Institute of Microbiology, Chinese Academy of Sciences cooperated to publish papers in Advanced Science online" Tonsillar microbiome-derived lantibiotics induce structural changes of IL-6 and IL-21 receptors and modulate host immunity ", reported the immunomodulatory effect of tonsil flora, discovered the molecular mechanism
by which tonsil microbiota antimicrobial peptide salivaricin inhibits autoimmune response by acting on interleukin (IL)-6 and -21 receptors.
For the first time, the researchers explored the immune mechanism of tonsil microbiota in the pathogenesis of rheumatoid arthritis (RA), and used metagenomic sequencing to find that the tonsil flora of RA patients was significantly abnormal, the gene abundance of antimicrobial peptide Salivaricin was significantly reduced, and it was significantly related to
changes in peripheral blood pro-inflammatory immune cells such as precursor follicular helper T cells, dendritic cells and plasma cells 。 The researchers further confirmed through in vitro experiments that salivaricin can significantly inhibit the differentiation of follicular helper T (Tfh) cells and the expression
of cytokine IL-21.
At the same time, using in vitro pull-down, surface plasmon resonance and circular dichromatography, it was found that Salivaricin can prevent and treat experimental arthritis
by binding to IL-6 and IL-21 receptors to block the activation of IL-6/IL-21-JAK-STAT3 signaling pathway.
Thus, this study demonstrates for the first time the important role of tonsil microbiota in maintaining immune balance, as well as the immunomodulatory mechanism of antimicrobial peptide Salivaricin in the pathogenesis of RA (click to read).
Li Jing, assistant researcher of Department of Rheumatology and Immunology, Peking University People's Hospital/Beijing Key Laboratory of Rheumatology, Dr.
Jin Jiayang, and Li Shenghui, visiting researcher of China Agricultural University, are co-first authors.
Professor Li Zhanguo, Professor He Jing and Professor Wang Jun are co-corresponding authors
.
Professor Qi Hai and Professor Guo Xiaohuan from the Institute of Immunology of Tsinghua University, Dr.
Qin Junjie from Shenzhen Puyuan Technology, and Professor Luo Tuoping from the Institute of Organic Chemistry of Peking University have made important contributions
.
JAMA Network Open Primary Sjögren syndrome (pSS) is a systemic autoimmune disease associated with dysregulation of immune cells for which there is no effective treatment
.
There is a need to study potential treatments
.
In October 2022, Professor Li Zhanguo's team from Peking University People's Hospital published a research result on immunotherapy for primary Sjögren's syndrome in JAMA Network Open: Efficacy and Safety of Low-Dose Interleukin-2 for Primary Sjögren's Syndrome: A Randomized Clinical Trial
。 The study demonstrated the effectiveness and safety
of low-dose IL-2 in the treatment of primary Sjogren syndrome.
The authors studied that after low-dose IL-2 treatment, the clinical symptoms and immune disorders of patients were significantly improved, providing a clinical and experimental basis for immunotherapy for Sjogren's syndrome (click to read).
Professor He Jing and Dr.
Chen Jiali are the first authors of this paper, and Professor Li Zhanguo and Professor Sun Xiaolin are the corresponding authors
.
(6) STTT This study found that glucocorticoid therapy led to a decrease in the overall proportion of Treg in 36% of SLE patients, and caused a decrease
in the expression of IL-2 signaling molecules such as CD25 on Treg in 45% of patients.
The combination of low-dose IL-2 significantly reversed this inhibition and improved Treg phenotype and functional molecule expression
.
IL-2 can enhance the expression
of Treg cell functional molecule CD39 and anti-apoptotic molecule Bcl2.
Hormonal therapy combined with low-dose IL-2 therapy can be reduced more significantlyPatients with SLEDAI, increased C3 and C4 levels
.
The study revealed that the combination of low-dose IL-2 when glucocorticoids were used to improve SLE and provided new ideas
for improving hormonal therapy.
The research has been accepted by the journal Signal Transduct Target Ther, and its application has been granted a national invention patent
.
Haotian Zhou and Xiaozhen Zhao of Peking University People's Hospital are co-first authors of the paper, and Professor Xiaolin Sun and Professor Li Zhanguo are co-corresponding authors
of the paper.
After the application of low dose IL2, the proportion of Treg (Figure A) and CD25 expression (Figure B) were significantly increased.
Using in vitro experiments on peripheral blood cells in healthy people and SLE patients, IL-2 can increase the level of pSTAT5 in CD4+ Treg cells (Figure C); Steroids combined with low-dose IL-2 therapy can significantly reduce SLEDAI and increase C3 and C4 levels (Figure D)
compared with glucocorticoids alone.
on the mechanism and treatment of rheumatoid arthritis and Sjogren's syndrome in first-class journals such as Lancet RH, JAMA Network Open, and Science Advances.
(1) The Lancet Regional Health is a study led by Peking University People's Hospital and participated by 17 centers of the Rheumatoid Arthritis Professional Group (RA-SIG) of the Asia-Pacific Rheumatology Alliance (APLAR), which conducted a real-world cross-sectional study of RA remission rate in APLAR countries and regions, and explored the relevant factors of drug treatment and clinical remission of this disease
。 The results were presented in The Lancet Regional Health (WP) under the title "Clinical remission of rheumatoid arthritis in a multicenter real-world study in Asia-Pacific region.
" ）” 2021,12; 15:100240 (click to read).
Sun Xing, Li Ru, and Cai Yueming are the joint works of this article, and Li Zhanguo and Li Ru are the joint correspondence
.
This research was supported
by the Macao Science and Technology Development Fund, Beijing Key Laboratory of Rheumatology, Beijing Rheumatoid Arthritis Key Special Fund of Beijing Municipal Science and Technology Commission, and Peking University Tsinghua Joint Center for Life Sciences (CLS).
Science Advances The rheumatology and immunology team of Peking University People's Hospital collaborated with the Beijing Genomics Institute to publish a research paper on the regulation of rheumatoid arthritis by intestinal flora in Science Advances Intestinal butyrate-metabolizing species contribute to autoantibody production and bone erosion in rheumatoid arthritis, and found an imbalance between butyric acid producing bacteria and butyric acid bacteria in RA patients through metagenomic and metabolomic analysis.
Associated with
the production of anti-CCP antibodies and joint deformities in patients.
This article covers basic, clinical and translational research
on rheumatoid arthritis.
Professor He Jing, postdoctoral fellow Li Jing, Department of Rheumatology and Immunology, Peking University People's Hospital, Yanan Chu from Beijing Genomics Research Institute, and Meng Qingren from Southern University of Science and Technology are co-first authors
of the paper.
Professor Li Zhanguo of Peking University People's Hospital and Peking University-Tsinghua Joint Center for Life Sciences, and Associate Researcher Kang Yu and Professor Yu Jun of Beijing Genomics Research Institute are co-corresponding authors
.
The clinical and scientific research team of the Department of Rheumatology and Immunology participated in the project and jointly completed the project
.
(3) Signal Transduction and Targeted Therapy In March 2022, Zhang Xiaoying et al.
published a research result of immunotherapy for rheumatoid arthritis in the journal Signal Transduction and Targeted Therapy Efficacy and safety of Ld-IL2 in combination with MTX in patients with active RA: a randomized trial
。 Demonstrated the effectiveness and safety
of low-dose IL-2 in the treatment of rheumatoid arthritis.
The authors also analyzed the predictors of efficacy in low-dose IL-2 therapy, the mechanism of methotrexate resistance, and the possible reversal of Lowdose IL2, providing a clinical and experimental basis
for this novel immunotherapy for rheumatoid arthritis.
Dr.
Zhang Xiaoying is the first author of this paper, and Professor Li Zhanguo and Professor He Jing are the corresponding authors
.
(4) Advanced Science In August 2022, Professor Li Zhanguo's research group and Professor Wang Jun's research group of the Institute of Microbiology, Chinese Academy of Sciences cooperated to publish papers in Advanced Science online" Tonsillar microbiome-derived lantibiotics induce structural changes of IL-6 and IL-21 receptors and modulate host immunity ", reported the immunomodulatory effect of tonsil flora, discovered the molecular mechanism
by which tonsil microbiota antimicrobial peptide salivaricin inhibits autoimmune response by acting on interleukin (IL)-6 and -21 receptors.
For the first time, the researchers explored the immune mechanism of tonsil microbiota in the pathogenesis of rheumatoid arthritis (RA), and used metagenomic sequencing to find that the tonsil flora of RA patients was significantly abnormal, the gene abundance of antimicrobial peptide Salivaricin was significantly reduced, and it was significantly related to
changes in peripheral blood pro-inflammatory immune cells such as precursor follicular helper T cells, dendritic cells and plasma cells 。 The researchers further confirmed through in vitro experiments that salivaricin can significantly inhibit the differentiation of follicular helper T (Tfh) cells and the expression
of cytokine IL-21.
At the same time, using in vitro pull-down, surface plasmon resonance and circular dichromatography, it was found that Salivaricin can prevent and treat experimental arthritis
by binding to IL-6 and IL-21 receptors to block the activation of IL-6/IL-21-JAK-STAT3 signaling pathway.
Thus, this study demonstrates for the first time the important role of tonsil microbiota in maintaining immune balance, as well as the immunomodulatory mechanism of antimicrobial peptide Salivaricin in the pathogenesis of RA (click to read).
Li Jing, assistant researcher of Department of Rheumatology and Immunology, Peking University People's Hospital/Beijing Key Laboratory of Rheumatology, Dr.
Jin Jiayang, and Li Shenghui, visiting researcher of China Agricultural University, are co-first authors.
Professor Li Zhanguo, Professor He Jing and Professor Wang Jun are co-corresponding authors
.
Professor Qi Hai and Professor Guo Xiaohuan from the Institute of Immunology of Tsinghua University, Dr.
Qin Junjie from Shenzhen Puyuan Technology, and Professor Luo Tuoping from the Institute of Organic Chemistry of Peking University have made important contributions
.
JAMA Network Open Primary Sjögren syndrome (pSS) is a systemic autoimmune disease associated with dysregulation of immune cells for which there is no effective treatment
.
There is a need to study potential treatments
.
In October 2022, Professor Li Zhanguo's team from Peking University People's Hospital published a research result on immunotherapy for primary Sjögren's syndrome in JAMA Network Open: Efficacy and Safety of Low-Dose Interleukin-2 for Primary Sjögren's Syndrome: A Randomized Clinical Trial
。 The study demonstrated the effectiveness and safety
of low-dose IL-2 in the treatment of primary Sjogren syndrome.
The authors studied that after low-dose IL-2 treatment, the clinical symptoms and immune disorders of patients were significantly improved, providing a clinical and experimental basis for immunotherapy for Sjogren's syndrome (click to read).
Professor He Jing and Dr.
Chen Jiali are the first authors of this paper, and Professor Li Zhanguo and Professor Sun Xiaolin are the corresponding authors
.
(6) STTT This study found that glucocorticoid therapy led to a decrease in the overall proportion of Treg in 36% of SLE patients, and caused a decrease
in the expression of IL-2 signaling molecules such as CD25 on Treg in 45% of patients.
The combination of low-dose IL-2 significantly reversed this inhibition and improved Treg phenotype and functional molecule expression
.
IL-2 can enhance the expression
of Treg cell functional molecule CD39 and anti-apoptotic molecule Bcl2.
Hormonal therapy combined with low-dose IL-2 therapy can be reduced more significantlyPatients with SLEDAI, increased C3 and C4 levels
.
The study revealed that the combination of low-dose IL-2 when glucocorticoids were used to improve SLE and provided new ideas
for improving hormonal therapy.
The research has been accepted by the journal Signal Transduct Target Ther, and its application has been granted a national invention patent
.
Haotian Zhou and Xiaozhen Zhao of Peking University People's Hospital are co-first authors of the paper, and Professor Xiaolin Sun and Professor Li Zhanguo are co-corresponding authors
of the paper.
After the application of low dose IL2, the proportion of Treg (Figure A) and CD25 expression (Figure B) were significantly increased.
Using in vitro experiments on peripheral blood cells in healthy people and SLE patients, IL-2 can increase the level of pSTAT5 in CD4+ Treg cells (Figure C); Steroids combined with low-dose IL-2 therapy can significantly reduce SLEDAI and increase C3 and C4 levels (Figure D)
compared with glucocorticoids alone.
—END—
The content is [iNature]
